23andMe Holding Co. (ME) Net Income
The trailing-twelve-month (TTM) net income for 23andMe Holding Co. (ME) is ($235.31 Million) — a year-over-year growth rate is not meaningful while net income is negative, so we show an honest n/m rather than a sign-ambiguous percentage. Net income represents the company's bottom line profit after all expenses, taxes, and interest.
ME Annual Net Income
Net Income (TTM)
($235.31M)
($235.31 Million)
Year-over-Year Change
n/m
not meaningful — net income is negative this period
Net Income CAGR
N/A
Compound annual growth rate unavailable
Net Income CAGR (Compound Annual Growth Rate)
1 Year
N/A
3 Year
N/A
5 Year
N/A
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Annual Net Income History
| Year | Net Income | YoY Change | % Change |
|---|---|---|---|
| 2025 | ($280.88M) | +$385.82M | — |
| 2024 | ($666.70M) | ($355.05M) | — |
| 2023 | ($311.66M) | ($94.17M) | — |
| 2022 | ($217.49M) | ($34.13M) | — |
| 2021 | ($183.36M) | +$67.50M | — |
| 2020 | ($250.86M) | ($67.33M) | — |
Net Income Growth Summary
TTM Growth
n/m
3-Year Avg Growth
n/m
5-Year Avg Growth
n/m
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage